Skip to main content

Advertisement

SpringerLink
Log in

Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody–Drug Conjugate Exposure in Solid Tumor

  • Research Article
  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

Antibody–drug conjugates (ADCs) rely on high expression of target antigens on cancer cells to effectively enter the cell and release a cytotoxic payload. Previous studies have shown that ADC efficacy is not always tied to antigen expression. However, our recent in vitro study suggests a linear relationship between antigen expression and the intracellular levels of the ADC payload. In this study, we have explored the relationship between antigen expression and intratumoral ADC exposure in vivo. Using trastuzumab-vc-MMAE (T-vc-MMAE) and four cell lines with varying expression of human epithelial growth factor receptor 2 (HER2), the pharmacokinetics of total trastuzumab, released (“free”) MMAE, and total MMAE were evaluated in a tumor xenograft model. Nude mice were implanted with tumors originating from BT-474, MDA-MB-453, MCF-7, and MDA-MB-468 cell lines and dosed with 10 mg/kg or 1 mg/kg of ADC. Observed data were mathematically characterized using a mechanism-based PK model. A strong positive correlation was observed between antigen expression levels and free/total MMAE exposure (R2 ≥ 0.91) (total MMAE being the sum of released and conjugated MMAE) within the tumor, but not for total trastuzumab exposure. The PK model was able to recapitulate plasma PK through simulation; however, the tumor PK was overpredicted or underpredicted in some cases potentially due to differences in tumor vasculature or extracellular matrix conditions. Our results indicate a linear relationship between antigen expression and tumor exposure of free/total ADC payload in vivo, validating our previous finding in vitro, while also revealing the need to understand complex physiology of the tumor to predict tumor PK of ADC and its components. Our findings also support the concept of antigen expression screening in patients for targeted therapies like ADCs to achieve the maximum therapeutic benefit of the treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Chau CH, Steeg PS, Figg WD. Antibody–drug conjugates for cancer. Lancet. 2019;394(10200):793–804.

    Article  CAS  Google Scholar 

  2. Collins DM, Bossenmaier B, Kollmorgen G, Niederfellner G. Acquired resistance to antibody-drug conjugates. Cancers (Basel). 2019;11(3).

  3. Mullard A. 2019 FDA drug approvals. Nat Rev Drug Discov. 2020;19(2):79–84.

    Article  CAS  Google Scholar 

  4. FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies [press release]. U.S. Food and Drug Administration, December 20, 2019.

  5. FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments [press release]. U.S. Food and Drug Administration, April 22, 2020.

  6. Kalim M, Chen J, Wang S, Lin C, Ullah S, Liang K, et al. Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates. Drug Des Dev Ther. 2017;11:2265–76.

    Article  CAS  Google Scholar 

  7. Bornstein GG. Antibody drug conjugates: preclinical considerations. AAPS J. 2015;17(3):525–34.

    Article  CAS  Google Scholar 

  8. Tolcher AW. Antibody drug conjugates: lessons from 20 years of clinical experience. Ann Oncol. 2016;27(12):2168–72.

    Article  CAS  Google Scholar 

  9. Lambert JM, Morris CQ. Antibody–drug conjugates (ADCs) for personalized treatment of solid tumors: a review. Adv Ther. 2017;34(5):1015–35.

    Article  CAS  Google Scholar 

  10. Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014;16(2):209.

    Article  Google Scholar 

  11. Li D, Poon KA, Yu SF, Dere R, Go M, Lau J, et al. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody–drug conjugate, is a potential treatment for non-Hodgkin lymphoma. Mol Cancer Ther. 2013;12(7):1255–65.

    Article  CAS  Google Scholar 

  12. O'Brien C, Cavet G, Pandita A, Hu X, Haydu L, Mohan S, et al. Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res. 2008;68(13):5380–9.

    Article  CAS  Google Scholar 

  13. Sharma S, Li Z, Bussing D, Shah DK. Evaluation of quantitative relationship between target expression and ADC exposure inside cancer cells. Drug Metab Dispos. 2020.

  14. Singh AP, Shah DK. Application of a PK-PD modeling and simulation-based strategy for clinical translation of antibody–drug conjugates: a case study with trastuzumab emtansine (T-DM1). AAPS J. 2017;19(4):1054–70.

    Article  CAS  Google Scholar 

  15. Singh AP, Maass KF, Betts AM, Wittrup KD, Kulkarni C, King LE, et al. Evolution of antibody–drug conjugate tumor disposition model to predict preclinical tumor pharmacokinetics of trastuzumab-emtansine (T-DM1). AAPS J. 2016;18(4):861–75.

    Article  CAS  Google Scholar 

  16. Shah DK, Haddish-Berhane N, Betts A. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin. J Pharmacokinet Pharmacodyn. 2012;39(6):643–59.

    Article  Google Scholar 

  17. Singh AP, Sharma S, Shah DK. Quantitative characterization of in vitro bystander effect of antibody–drug conjugates. J Pharmacokinet Pharmacodyn. 2016;43(6):567–82.

    Article  CAS  Google Scholar 

  18. Li Y, Gu C, Gruenhagen J, Yehl P, Chetwyn NP, Medley CD. An enzymatic deconjugation method for the analysis of small molecule active drugs on antibody–drug conjugates. MAbs. 2016;8(4):698–705.

    Article  CAS  Google Scholar 

  19. Shah DK, King LE, Han X, Wentland JA, Zhang Y, Lucas J, et al. A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody–drug conjugate. AAPS J. 2014;16(3):452–63.

    Article  CAS  Google Scholar 

  20. Maass KF, Kulkarni C, Betts AM, Wittrup KD. Determination of cellular processing rates for a trastuzumab–maytansinoid antibody–drug conjugate (ADC) highlights key parameters for ADC design. AAPS J. 2016;18(3):635–46.

    Article  CAS  Google Scholar 

  21. D'Argenio DZ, Schumitzky A, Wang X. ADAPT 5 User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. 2009.

  22. Mathworks. SimBiology: User's Guide (R2018b). 2018.

  23. Flores BE. A pragmatic view of accuracy measurement in forecasting. Omega. 1986;14(2):93–8.

    Article  Google Scholar 

  24. Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J. Antibody–drug conjugates: a comprehensive review. Mol Cancer Res. 2020;18(1):3–19.

    Article  CAS  Google Scholar 

  25. Martin LP, Konner JA, Moore KN, Seward SM, Matulonis UA, Perez RP, et al. Characterization of folate receptor alpha (FRalpha) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of the FRalpha-targeting antibody–drug conjugate mirvetuximab soravtansine. Gynecol Oncol. 2017;147(2):402–7.

    Article  CAS  Google Scholar 

  26. Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29(4):398–405.

    Article  CAS  Google Scholar 

  27. Polson AG, Ho WY, Ramakrishnan V. Investigational antibody–drug conjugates for hematological malignancies. Expert Opin Investig Drugs. 2011;20(1):75–85.

    Article  CAS  Google Scholar 

  28. Tong XM, Feng L, Suthe SR, Weng TH, Hu CY, Liu YZ, et al. Therapeutic efficacy of a novel humanized antibody–drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy. J Immunother Cancer. 2019;7(1):250.

    Article  Google Scholar 

  29. Le Joncour V, Martins A, Puhka M, Isola J, Salmikangas M, Laakkonen P, et al. A novel anti-HER2 antibody-drug conjugate XMT-1522 for HER2-positive breast and gastric cancers resistant to trastuzumab emtansine. Mol Cancer Ther. 2019;18(10):1721–30.

    Article  Google Scholar 

  30. Mosher R, Vogel C, Shaw P, Zielinski D, Boesler C, Mühleisen A, et al. Target expression/efficacy relationship of XMT-1522, a HER2-targeting antibody drug conjugate (ADC), in an unselected series of non-small cell lung cancer (NSCLC) primary human carcinoma xenografts. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; Dublin, Ireland; 2018.

  31. McLarty K, Cornelissen B, Scollard DA, Done SJ, Chun K, Reilly RM. Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. Eur J Nucl Med Mol Imaging. 2009;36(1):81–93.

    Article  CAS  Google Scholar 

  32. Harrell JC, Pfefferle AD, Zalles N, Prat A, Fan C, Khramtsov A, et al. Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis. Clin Exp Metastasis. 2014;31(1):33–45.

    Article  CAS  Google Scholar 

  33. Makawita S, Meric-Bernstam F. Antibody–drug conjugates: patient and treatment selection. Am Soc Clin Oncol Educ Book. 2020;40:1–10.

    PubMed  Google Scholar 

  34. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol. 2004;22(6):701–6.

    Article  CAS  Google Scholar 

  35. Palm S, Enmon RM Jr, Matei C, Kolbert KS, Xu S, Zanzonico PB, et al. Pharmacokinetics and biodistribution of (86)Y-trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. J Nucl Med. 2003;44(7):1148–55.

    CAS  PubMed  Google Scholar 

  36. Ammons WS, Bauer RJ, Horwitz AH, Chen ZJ, Bautista E, Ruan HH, et al. In vitro and in vivo pharmacology and pharmacokinetics of a human engineered monoclonal antibody to epithelial cell adhesion molecule. Neoplasia. 2003;5(2):146–54.

    Article  CAS  Google Scholar 

  37. Li F, Ulrich ML, Shih VF, Cochran JH, Hunter JH, Westendorf L, et al. Mouse strains influence clearance and efficacy of antibody and antibody–drug conjugate via Fc-FcgammaR interaction. Mol Cancer Ther. 2019;18(4):780–7.

    Article  CAS  Google Scholar 

  38. Kurebayashi J, Otsuki T, Kunisue H, Mikami Y, Tanaka K, Yamamoto S, et al. Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn J Cancer Res. 1999;90(9):977–81.

    Article  CAS  Google Scholar 

  39. Farooqi AA, Siddik ZH. Platelet-derived growth factor (PDGF) signalling in cancer: rapidly emerging signalling landscape. Cell Biochem Funct. 2015;33(5):257–65.

    Article  CAS  Google Scholar 

  40. Shibata A, Nagaya T, Imai T, Funahashi H, Nakao A, Seo H. Inhibition of NF-kappaB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells. Breast Cancer Res Treat. 2002;73(3):237–43.

    Article  CAS  Google Scholar 

  41. Chen R, Hou J, Newman E, Kim Y, Donohue C, Liu X, et al. CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol Cancer Ther. 2015;14(6):1376–84.

    Article  CAS  Google Scholar 

  42. Williams M, Spreafico A, Vashisht K, Hinrichs MJ. Patient selection strategies to maximize therapeutic index of antibody–drug conjugates: prior approaches and future directions. Mol Cancer Ther. 2020;19(9):1770–83.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

This project was funded by the Center for Protein Therapeutics (CPT) at the University at Buffalo (UB). D.K.S. is supported by NIH grants GM114179, AI138195, and R01CA246785.

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, The State University of New York at Buffalo, Buffalo, New York, USA

    David Bussing, Sharad Sharma, Zhe Li, Lyndsey F. Meyer & Dhaval K. Shah

  2. NBE-PK, Research and Development, Boehringer Ingelheim Pharmaceuticals Inc, 900 Ridgebury Rd., P.O. Box 368, Ridgefield, Connecticut, 06877-0368, USA

    Sharad Sharma

Authors
  1. David Bussing
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sharad Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhe Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lyndsey F. Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dhaval K. Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Sharad Sharma or Dhaval K. Shah.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

ESM 1

(DOCX 1021 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bussing, D., Sharma, S., Li, Z. et al. Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody–Drug Conjugate Exposure in Solid Tumor. AAPS J 23, 56 (2021). https://doi.org/10.1208/s12248-021-00584-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1208/s12248-021-00584-y

KEY WORDS

Search

Navigation